Chemical Structure Searching for the Array of Pharmaceutical Intelligence Tools
News Sep 05, 2005
Wolters Kluwer Health has announced a partnership with CambridgeSoft of Cambridge, Mass., to market chemical structure search tools for drug discovery scientists and pharmaceutical chemists.
At the annual meeting of the American Chemical Society (ACS), the companies demonstrated their first joint product, a software module that is designed to allow scientists to use ChemDraw®, the chemical-drawing software, to search by chemical structure for all of the compounds in the existing Adis R&D Insight® database.
Marketed by Wolters Kluwer Health, Adis R&D Insight is the industry's authoritative pipeline intelligence tool that is designed to feature a database of 20,000 compounds.
CambridgeSoft's technology is designed to convert chemical compound names into their associated chemical structures and makes them searchable.
According to Wolters, using the module, drug discovery scientists can query the vast, text-based Adis R&D Insight database using their own language and the resulting benefit is that users can evaluate a structure in the context of related compounds.
"Using our new structure searching module, scientists can check to see if a target molecule is already in development or if it's near clinical trials," said John Monahan, President and CEO of Wolters Kluwer Health, Pharma Solutions.
He adds, "By harnessing the power of ChemDraw and Adis R&D Insight, we've made it easier for scientists to identify a potentially competitive compound earlier in the development process."
"CambridgeSoft is pleased to be partnering with Wolters Kluwer Health," said Michael G. Tomasic, Chairman and CEO of CambridgeSoft.
He adds, "Combining content provided by Wolters Kluwer Health with the leading chemical structure search technology, including ChemOffice and ChemDraw, from CambridgeSoft enhances the ability of the scientific community to search, analyze, and make decisions relevant to the direction of the research."
Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective. In the face of this reality, researcher Prof. Dennis Wright has improved upon a new way to thwart the tricky pathogen, mycobacterium tuberculosis.READ MORE
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE